Germany, Spain, and Italy conduct well-documented hypertension stem-cell trials within university cardiovascular departments. Poland and Czech Republic offer active protocols at lower cost. South Korea maintains several recruiting hypertension trials. United States capacity is fragmented; cardiovascular research centres at major academic medical centres conduct some MSC-hypertension trials. Brazil and several Latin American countries have active programmes. Selection should prioritise centres with cardiovascular-imaging capabilities, published safety data, and ClinicalTrials.gov registration over claims of guaranteed blood-pressure reduction.
Arterial hypertension stem-cell treatment costs typically range €3,500–6,500 per infusion, depending on cell source and formulation. Exosome-based therapies, when offered, may cost similarly to MSCs or slightly higher due to manufacturing complexity. Single-infusion protocols are more common in hypertension than multi-cycle regimens, potentially reducing total expense compared to other conditions. Placental MSCs are favoured for cost-efficiency and cardiovascular safety profile. Home-based blood-pressure monitoring adds minimal cost but is essential for outcome assessment. European hospital-affiliated programmes typically charge €3,500–5,000; private cardiovascular clinics may exceed €6,500. Insurance rarely covers experimental therapy, necessitating out-of-pocket payment.
我是候选人吗？ → · Arterial Hypertension: full overview → · 动脉高血压成本 → · Cost →
由 StemCellAtlas 的编辑团队进行医学审查，与Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) 合作诊所 Stem Plus（索菲亚）的，根据 ISSCR、FDA 和 EMA 指南。 Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估